2019 Novel Coronavirus (2019-nCoV) Products

As of April 3, 2020, IDT has produced primer and probe kits sufficient to enable approximately 23 million tests to be conducted in the US pursuant to the CDC EUA testing protocol.

IDT has received inquiries from researchers from around the world who are interested in rapidly obtaining assays and developing vaccines targeting the novel coronavirus (2019-nCoV/SARS-CoV-2) identified in Wuhan, China. Supporting these efforts, the CDC and the Chinese government have sequenced and submitted the coronavirus genome to the US NCBI GenBank® database. With our worldwide manufacturing capabilities, IDT is uniquely able to provide robust qPCR assays while avoiding contamination issues from synthesis of controls and related gene fragments.

Virus detection

2019-nCoV CDC qPCR Probe Assay »

The US Centers for Disease Control and Prevention (CDC) has designed RT-PCR assays and published a protocol for the detection of the 2019-nCoV. IDT provides primers and probes for these CDC assays for the identification of virus.

Don’t see what you need for your nCoV experiments?

We can accommodate custom requests.

Contact us

Vaccine development

Genes & gene fragments »

Advances in gene synthesis mean that subunit vaccines can be developed quickly from one or more antigen-presenting viral genes or peptide sequences, which circumvents the need for scientists to handle live and potentially dangerous pathogens, and eliminates the time needed to clone DNA fragments.

Use IDT double-stranded DNA fragments to create synthetic proteins designed as safe reagents for vaccine research. IDT offers 3 convenient options: linear gBlocks Gene Fragments, eBlocks Gene Fragments, or Custom Genes cloned into vectors. These are available in varying lengths and synthesis scales. Start your order, and we will help you choose the format that best fits your needs.

Ready to order?  Place your order using: https://www.idtdna.com/pages/products/genes-and-gene-fragments.

CDC Information for laboratories

Access the CDC’s latest laboratory guidance for 2019-nCoV RT-PCR assays.

Information for laboratories

Media Information

IDT is honored to be the first company in the nation to have our primer and probe kits approved by the CDC for use as a key component of the CDC EUA testing protocol for the diagnosis and detection of COVID-19. We are proud to have rapidly achieved large-scale manufacturing of this key component which enables testing of millions of Americans for COVID-19.

For media inquiries about IDT’s role in the fight against COVID-19, please contact:

IDT Public Relations, idtpr@idtdna.com
Anna Blyth, ablyth@apcoworldwide.com
Iris Shaffer, ishaffer@apcoworldwide.com

Get up to date. Stay up to date.
Sign up to receive IDT news and updates.

Your Advocate for the Genomics Age